ASCO 2020 annual meeting
![ASCO 2020 annual meeting](/images/conferences/american-society-of-clinical-oncology-annual-congress-asco-2020_20200708154843_big.jpeg)
Programme du congrès
Lieu : Chicago, Illinois
Pays : Etats-Unis
Langue : ENG
Date de début :
Date de fin :
Spécialités : Oncologie
Cancer du sein : identification de biomarqueurs potentiels pour prédire lefficacité du ribociclib
![Cancer du sein : identification de biomarqueurs potentiels pour prédire lefficacité du ribociclib Cancer du sein : identification de biomarqueurs potentiels pour prédire lefficacité du ribociclib](/images/videos/cancer-du-sein-identification-de-biomarqueurs-potentiels-pour-pr-dire-l-efficacit-du-ribociclib_20200611171554.png)
- Date : 29/05/2020
- 6 0
Brian Jonas, ASCO20: Venetoclax combination treatment in older patients with acute myeloid leukemia
![Brian Jonas, ASCO20: Venetoclax combination treatment in older patients with acute myeloid leukemia Brian Jonas, ASCO20: Venetoclax combination treatment in older patients with acute myeloid leukemia](/images/videos/brian-jonas-asco20-venetoclax-combination-treatment-in-older-patients-with-acute-myeloid-leukemia_20200604164341.png)
- Date : 29/05/2020
- 3 0
PART 1: Yuval Shaked, ASCO 2020: Host Response Profiling for Melanoma Patients
![PART 1: Yuval Shaked, ASCO 2020: Host Response Profiling for Melanoma Patients PART 1: Yuval Shaked, ASCO 2020: Host Response Profiling for Melanoma Patients](/images/videos/part-1-yuval-shaked-asco-2020-host-response-profiling-for-melanoma-patients_20200604164316.png)
- Date : 29/05/2020
- 1 0
John Kuruvilla, ASCO20: Results of the KEYNOTE-204 Phase III Trial in Patients with cHL
![John Kuruvilla, ASCO20: Results of the KEYNOTE-204 Phase III Trial in Patients with cHL John Kuruvilla, ASCO20: Results of the KEYNOTE-204 Phase III Trial in Patients with cHL](/images/videos/john-kuruvilla-asco20-results-of-the-keynote-204-phase-iii-trial-in-patients-with-chl_20200604164330.png)
- Date : 29/05/2020
- 1 0
PART 2: Yuval Shaked, ASCO 2020: Host Response Profiling for Melanoma Patients
![PART 2: Yuval Shaked, ASCO 2020: Host Response Profiling for Melanoma Patients PART 2: Yuval Shaked, ASCO 2020: Host Response Profiling for Melanoma Patients](/images/videos/part-2-yuval-shaked-asco-2020-host-response-profiling-for-melanoma-patients_20200604164353.png)
- Date : 29/05/2020
- 1 0
ASCO Global Webinar Series: April 21, Laboratory Research & Screening Patients
![ASCO Global Webinar Series: April 21, Laboratory Research & Screening Patients ASCO Global Webinar Series: April 21, Laboratory Research & Screening Patients](/images/videos/asco-global-webinar-series-april-21-laboratory-research-screening-patients_20200820115817.png)
- Date : 02/06/2020
- 1 0
MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use
![MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use](/images/videos/mindact-long-term-results-70-gene-signature-mammaprint-to-guide-adjuvant-chemotherapy-use_20200821140929.png)
- Date : 29/05/2020
- 1 0
PANDA: Combining panitumumab with FOLFOX or 5FU in elderly patients with RAS-BRAF WT
![PANDA: Combining panitumumab with FOLFOX or 5FU in elderly patients with RAS-BRAF WT PANDA: Combining panitumumab with FOLFOX or 5FU in elderly patients with RAS-BRAF WT](/images/videos/panda-combining-panitumumab-with-folfox-or-5fu-in-elderly-patients-with-ras-braf-wt_20200821141335.png)
- Date : 29/05/2020
- 1 0
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients
![Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients](/images/videos/total-neoadjuvant-therapy-with-mfolfirinox-versus-preoperative-chemoradiation-in-patients_20200821141522.png)
- Date : 29/05/2020
- 1 0
Cisplatin +/- veliparib in metastatic TNBC and/or germline BRCA-associated breast cancer
![Cisplatin +/- veliparib in metastatic TNBC and/or germline BRCA-associated breast cancer Cisplatin +/- veliparib in metastatic TNBC and/or germline BRCA-associated breast cancer](/images/videos/cisplatin-veliparib-in-metastatic-tnbc-and-or-germline-brca-associated-breast-cancer_20200821142234.png)
- Date : 29/05/2020
- 1 0
Le programme CAPRI démontre l'efficacité du suivi à distance des traitements oraux
![Le programme CAPRI démontre l'efficacité du suivi à distance des traitements oraux Le programme CAPRI démontre l'efficacité du suivi à distance des traitements oraux](/images/videos/le-programme-capri-d-montre-lefficacit-du-suivi-distance-des-traitements-oraux_20200611171450.png)
- Date : 29/05/2020
- 0 0
Résultats prometteurs d'une association de thérapies ciblées dans le gliome de l'enfant
![Résultats prometteurs d'une association de thérapies ciblées dans le gliome de l'enfant Résultats prometteurs d'une association de thérapies ciblées dans le gliome de l'enfant](/images/videos/r-sultats-prometteurs-dune-association-de-th-rapies-cibl-es-dans-le-gliome-de-lenfant_20200611171518.png)
- Date : 29/05/2020
- 0 0
ASCO Global Webinar Series July 28, Experiences and Lessons During the COVID-19 Pandemic
![ASCO Global Webinar Series July 28, Experiences and Lessons During the COVID-19 Pandemic ASCO Global Webinar Series July 28, Experiences and Lessons During the COVID-19 Pandemic](/images/videos/asco-global-webinar-series-july-28-experiences-and-lessons-during-the-covid-19-pandemic_20200820115710.png)
- Date : 28/06/2020
- 0 0
ASCO Global Webinar Series: June 30, Learning Through Collaboration -- Population-Based Research
![ASCO Global Webinar Series: June 30, Learning Through Collaboration -- Population-Based Research ASCO Global Webinar Series: June 30, Learning Through Collaboration -- Population-Based Research](/images/videos/asco-global-webinar-series-june-30-learning-through-collaboration-population-based-research_20200820115723.png)
- Date : 30/06/2020
- 0 0
ASCO Global Webinar Series: April 14, Experiences and Lessons During the COVID 19 Pandemic
![ASCO Global Webinar Series: April 14, Experiences and Lessons During the COVID 19 Pandemic ASCO Global Webinar Series: April 14, Experiences and Lessons During the COVID 19 Pandemic](/images/videos/asco-global-webinar-series-april-14-experiences-and-lessons-during-the-covid-19-pandemic_20200820115801.png)
- Date : 14/04/2020
- 0 0
ASCO Global Webinar Series: May 12, Practice Plans for Transitioning Back to Standard Operations
![ASCO Global Webinar Series: May 12, Practice Plans for Transitioning Back to Standard Operations ASCO Global Webinar Series: May 12, Practice Plans for Transitioning Back to Standard Operations](/images/videos/asco-global-webinar-series-may-12-practice-plans-for-transitioning-back-to-standard-operations_20200820115858.png)
- Date : 12/04/2020
- 0 0
Perioperative novel systemic immunotherapy-based approaches in urinary cancers
![Perioperative novel systemic immunotherapy-based approaches in urinary cancers Perioperative novel systemic immunotherapy-based approaches in urinary cancers](/images/videos/perioperative-novel-systemic-immunotherapy-based-approaches-in-urinary-cancers_20200821140917.png)
- Date : 29/05/2020
- 0 0
COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF
![COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF](/images/videos/combi-ad-trial-adjuvant-dabrafenib-plus-trametinib-in-patients-with-resected-stage-iii-braf_20200821140940.png)
- Date : 29/05/2020
- 0 0
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer
![IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer](/images/videos/imvigor130-atezolizumab-with-or-without-chemotherapy-in-metastatic-urothelial-cancer_20200821140950.png)
- Date : 29/05/2020
- 0 0
FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2020
![FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2020 FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2020](/images/videos/fgfr-inhibitors-in-bladder-cancer-testing-screening-and-highlights-from-asco-2020_20200821141028.png)
- Date : 29/05/2020
- 0 0
High-dose twice daily thoracic radiotherapy in limited disease small-cell lung cancer
![High-dose twice daily thoracic radiotherapy in limited disease small-cell lung cancer High-dose twice daily thoracic radiotherapy in limited disease small-cell lung cancer](/images/videos/high-dose-twice-daily-thoracic-radiotherapy-in-limited-disease-small-cell-lung-cancer_20200821141040.png)
- Date : 29/05/2020
- 0 0
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients
![ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients](/images/videos/aspen-results-of-a-phase-iii-randomised-trial-of-zanubrutinib-vs-ibrutinib-for-patients_20200821141103.png)
- Date : 29/05/2020
- 0 0
Reducing damage to swallowing muscles during radiotherapy for head and neck cancers
![Reducing damage to swallowing muscles during radiotherapy for head and neck cancers Reducing damage to swallowing muscles during radiotherapy for head and neck cancers](/images/videos/reducing-damage-to-swallowing-muscles-during-radiotherapy-for-head-and-neck-cancers_20200821141113.png)
- Date : 29/05/2020
- 0 0
HCRN GU16-260: Nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients
![HCRN GU16-260: Nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients HCRN GU16-260: Nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients](/images/videos/hcrn-gu16-260-nivolumab-and-salvage-nivolumab-ipilimumab-in-treatment-na-ve-patients_20200821141156.png)
- Date : 29/05/2020
- 0 0
PARP inhibitors in prostate cancer: Guidelines, who to test and the patient pathway
![PARP inhibitors in prostate cancer: Guidelines, who to test and the patient pathway PARP inhibitors in prostate cancer: Guidelines, who to test and the patient pathway](/images/videos/parp-inhibitors-in-prostate-cancer-guidelines-who-to-test-and-the-patient-pathway_20200821141255.png)
- Date : 29/05/2020
- 0 0
Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours
![Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours](/images/videos/early-safety-from-a-trial-of-talimogene-laherparepvec-t-vec-injected-into-liver-tumours_20200821141307.png)
- Date : 29/05/2020
- 0 0
3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and neck
![3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and neck 3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and neck](/images/videos/3-weekly-cisplatin-or-weekly-cisplatin-for-squamous-cell-carcinoma-of-head-and-neck_20200821141349.png)
- Date : 29/05/2020
- 0 0
US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition
![US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition](/images/videos/us-mm-6-long-term-proteasome-inhibition-in-multiple-myeloma-following-an-in-class-transition_20200821141402.png)
- Date : 29/05/2020
- 0 0
Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients
![Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients](/images/videos/three-versus-six-months-of-adjuvant-oxaliplatin-and-fluoropyrimidine-based-therapy-for-patients_20200821141446.png)
- Date : 29/05/2020
- 0 0
Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer
![Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer](/images/videos/osimertinib-plus-gefitinib-for-treatment-of-egfr-mutated-non-small-cell-lung-cancer_20200821141459.png)
- Date : 29/05/2020
- 0 0
Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk
![Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk](/images/videos/comparing-pevonedistat-plus-azacitidine-versus-azacitidine-alone-in-patients-with-higher-risk_20200821141535.png)
- Date : 29/05/2020
- 0 0
FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma
![FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma](/images/videos/forte-trial-minimal-residual-disease-evaluation-in-newly-diagnosed-multiple-myeloma_20200821141549.png)
- Date : 29/05/2020
- 0 0
Perioperative chemotherapy with mfolfirinox vs gemcitabine/nab-paclitaxel for resectable
![Perioperative chemotherapy with mfolfirinox vs gemcitabine/nab-paclitaxel for resectable Perioperative chemotherapy with mfolfirinox vs gemcitabine/nab-paclitaxel for resectable](/images/videos/perioperative-chemotherapy-with-mfolfirinox-vs-gemcitabine-nab-paclitaxel-for-resectable_20200821141602.png)
- Date : 29/05/2020
- 0 0
CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC
![CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC](/images/videos/ctc-count-as-a-prognostic-marker-for-androgen-deprivation-plus-orteronel-or-bicalutamide-in-mcspc_20200821141633.png)
- Date : 29/05/2020
- 0 0
TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochemotherapy
![TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochemotherapy TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochemotherapy](/images/videos/trophimmun-avelumab-for-gestational-trophoblastic-tumours-resistant-to-monochemotherapy_20200821141650.png)
- Date : 29/05/2020
- 0 0
KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal
![KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal](/images/videos/keynote-177-results-pembrolizumab-versus-chemotherapy-for-patients-with-msi-h-dmmr-colorectal_20200821141706.png)
- Date : 29/05/2020
- 0 0
Timing of response to venetoclax combination treatment in older patients with acute myeloid
![Timing of response to venetoclax combination treatment in older patients with acute myeloid Timing of response to venetoclax combination treatment in older patients with acute myeloid](/images/videos/timing-of-response-to-venetoclax-combination-treatment-in-older-patients-with-acute-myeloid_20200821141721.png)
- Date : 29/05/2020
- 0 0
Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myeloma
![Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myeloma Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myeloma](/images/videos/venetoclax-with-bortezomib-and-dexamethasone-in-relapsed-refractory-multiple-myeloma_20200821141847.png)
- Date : 29/05/2020
- 0 0
LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progressing
![LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progressing LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progressing](/images/videos/lupsma-vs-cabazitaxel-in-metastatic-castration-resistant-prostate-cancer-progressing_20200821141900.png)
- Date : 29/05/2020
- 0 0
Cumulative incidence of financial hardship in metastatic colorectal cancer patients
![Cumulative incidence of financial hardship in metastatic colorectal cancer patients Cumulative incidence of financial hardship in metastatic colorectal cancer patients](/images/videos/cumulative-incidence-of-financial-hardship-in-metastatic-colorectal-cancer-patients_20200821141915.png)
- Date : 29/05/2020
- 0 0
Association of BRCA alternations with response to PARP inhibitors in metastatic
![Association of BRCA alternations with response to PARP inhibitors in metastatic Association of BRCA alternations with response to PARP inhibitors in metastatic](/images/videos/association-of-brca-alternations-with-response-to-parp-inhibitors-in-metastatic_20200821141945.png)
- Date : 29/05/2020
- 0 0
COM701 as a monotherapy and in combination with nivolumab for various advanced solid tumours
![COM701 as a monotherapy and in combination with nivolumab for various advanced solid tumours COM701 as a monotherapy and in combination with nivolumab for various advanced solid tumours](/images/videos/com701-as-a-monotherapy-and-in-combination-with-nivolumab-for-various-advanced-solid-tumours_20200821141959.png)
- Date : 29/05/2020
- 0 0
Teclistamab for patients with heavily pretreated relapsed or refractory multiple myeloma
![Teclistamab for patients with heavily pretreated relapsed or refractory multiple myeloma Teclistamab for patients with heavily pretreated relapsed or refractory multiple myeloma](/images/videos/teclistamab-for-patients-with-heavily-pretreated-relapsed-or-refractory-multiple-myeloma_20200821142012.png)
- Date : 29/05/2020
- 0 0
E2108: Systemic therapy plus early local therapy versus systemic therapy alone
![E2108: Systemic therapy plus early local therapy versus systemic therapy alone E2108: Systemic therapy plus early local therapy versus systemic therapy alone](/images/videos/e2108-systemic-therapy-plus-early-local-therapy-versus-systemic-therapy-alone_20200821142027.png)
- Date : 29/05/2020
- 0 0
The paediatric precision oncology study INFORM: Clinical outcome and benefit for molecular
![The paediatric precision oncology study INFORM: Clinical outcome and benefit for molecular The paediatric precision oncology study INFORM: Clinical outcome and benefit for molecular](/images/videos/the-paediatric-precision-oncology-study-inform-clinical-outcome-and-benefit-for-molecular_20200821142040.png)
- Date : 29/05/2020
- 0 0
Maintenance avelumab plus best supportive care (BSC) versus BSC alone after chemotherapy
![Maintenance avelumab plus best supportive care (BSC) versus BSC alone after chemotherapy Maintenance avelumab plus best supportive care (BSC) versus BSC alone after chemotherapy](/images/videos/maintenance-avelumab-plus-best-supportive-care-bsc-versus-bsc-alone-after-chemotherapy_20200821142055.png)
- Date : 29/05/2020
- 0 0
KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy
![KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy](/images/videos/keynote-604-pembrolizumab-plus-etoposide-and-platinum-as-a-first-line-therapy_20200821142109.png)
- Date : 29/05/2020
- 0 0
CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy
![CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy](/images/videos/cartitude-1-jnj-4528-a-b-cell-maturation-antigen-bcma-directed-car-t-cell-therapy_20200821142205.png)
- Date : 29/05/2020
- 0 0
ASCO 2020: Pembrolizumab plus chemotherapy for patients with metastatic triple-negative
![ASCO 2020: Pembrolizumab plus chemotherapy for patients with metastatic triple-negative ASCO 2020: Pembrolizumab plus chemotherapy for patients with metastatic triple-negative](/images/videos/asco-2020-pembrolizumab-plus-chemotherapy-for-patients-with-metastatic-triple-negative_20200821142248.png)
- Date : 29/05/2020
- 0 0
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma
![CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma](/images/videos/candor-trial-design-investigating-kdd-versus-kd-in-relapsed-refractory-multiple-myeloma_20200821142330.png)
- Date : 29/05/2020
- 0 0
AGMT_MM-1: Investigating the oral microbiome in patients with relapsed/refractory multiple myeloma
![AGMT_MM-1: Investigating the oral microbiome in patients with relapsed/refractory multiple myeloma AGMT_MM-1: Investigating the oral microbiome in patients with relapsed/refractory multiple myeloma](/images/videos/agmt-mm-1-investigating-the-oral-microbiome-in-patients-with-relapsed-refractory-multiple-myeloma_20200821142346.png)
- Date : 29/05/2020
- 0 0
Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodkin lymphomavvvv
![Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodkin lymphomavvvv Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodkin lymphomavvvv](/images/videos/pembrolizumab-vs-brentuximab-vedotin-in-relapsed-or-refractory-classic-hodkin-lymphomavvvv_20200821142400.png)
- Date : 29/05/2020
- 0 0
KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advanced clear
![KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advanced clear KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advanced clear](/images/videos/keynote-427-updates-first-line-pembrolizumab-monotherapy-in-patients-with-advanced-clear_20200821142412.png)
- Date : 29/05/2020
- 0 0
Association of gene expression with clinical outcomes in advanced RCC patients treated
![Association of gene expression with clinical outcomes in advanced RCC patients treated Association of gene expression with clinical outcomes in advanced RCC patients treated](/images/videos/association-of-gene-expression-with-clinical-outcomes-in-advanced-rcc-patients-treated_20200821142425.png)
- Date : 29/05/2020
- 0 0
FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-refractory
![FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-refractory FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-refractory](/images/videos/fraction-rcc-evaluating-nivolumab-plus-ipilimumab-in-patients-with-treatment-refractory_20200821142450.png)
- Date : 29/05/2020
- 0 0
Sélection de congrès
14èmes Journées des Référentiels en Soins Oncologiques de support - AFSOS 2024
![14èmes Journées des Référentiels en Soins Oncologiques de support - AFSOS 2024](/images/conferences/14-mes-journ-es-des-r-f-rentiels-en-soins-oncologiques-de-support-afsos-2024_medium.png)
- Date : 12/12/2024
-
202
0
45emes Journées de la Société Française de Sénologie et de Pathologie Mammaire - SFSPM 2024
![45emes Journées de la Société Française de Sénologie et de Pathologie Mammaire - SFSPM 2024](/images/conferences/45emes-journ-es-de-la-soci-t-fran-aise-de-s-nologie-et-de-pathologie-mammaire-sfspm-2024_medium.jpeg)
- Date : 06/11/2024
-
841
0